PURPOSE: To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: TEL gene status was determined for 926 patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 16 trials and patients were observed for a median time of 8 years. RESULTS: Rearrangements of the TEL gene were detected in 244 patients (26%). The estimated 5-year event-free survival rate (+/- SE) for patients with TEL rearrangements was 86% +/- 2%, compared with 72% +/- 2% for those with germline TEL (P < .0001). TEL rearrangements were associated with a superior outcome among patients with standard-risk ALL, high-risk ALL, and rapid early responses to therapy. In a multivariate analysis that included risk group, sex, and day 15 marrow status, TEL status was an independent predictor of outcome (P = .0002). CONCLUSION: We conclude that TEL gene status should be incorporated into risk classification schemes and suggest that patients who have standard-risk features, the TEL-AML1 fusion, and rapid early responses to therapy, should be treated with antimetabolite-based therapy designed to maintain their high cure rates and avoid late effects.
PURPOSE: To prospectively determine the prognostic significance of the TEL-AML1 fusion in children with acute lymphoblastic leukemia (ALL). PATIENTS AND METHODS: TEL gene status was determined for 926 patients with B-precursor ALL enrolled on the Pediatric Oncology Group ALinC 16 trials and patients were observed for a median time of 8 years. RESULTS: Rearrangements of the TEL gene were detected in 244 patients (26%). The estimated 5-year event-free survival rate (+/- SE) for patients with TEL rearrangements was 86% +/- 2%, compared with 72% +/- 2% for those with germline TEL (P < .0001). TEL rearrangements were associated with a superior outcome among patients with standard-risk ALL, high-risk ALL, and rapid early responses to therapy. In a multivariate analysis that included risk group, sex, and day 15 marrow status, TEL status was an independent predictor of outcome (P = .0002). CONCLUSION: We conclude that TEL gene status should be incorporated into risk classification schemes and suggest that patients who have standard-risk features, the TEL-AML1 fusion, and rapid early responses to therapy, should be treated with antimetabolite-based therapy designed to maintain their high cure rates and avoid late effects.
Authors: M B Harris; J J Shuster; A Carroll; A T Look; M J Borowitz; W M Crist; R Nitschke; J Pullen; C P Steuber; V J Land Journal: Blood Date: 1992-06-15 Impact factor: 22.113
Authors: Kirk R Schultz; D Jeanette Pullen; Harland N Sather; Jonathan J Shuster; Meenakshi Devidas; Michael J Borowitz; Andrew J Carroll; Nyla A Heerema; Jeffrey E Rubnitz; Mignon L Loh; Elizabeth A Raetz; Naomi J Winick; Stephen P Hunger; William L Carroll; Paul S Gaynon; Bruce M Camitta Journal: Blood Date: 2006-09-26 Impact factor: 22.113
Authors: M Smith; D Arthur; B Camitta; A J Carroll; W Crist; P Gaynon; R Gelber; N Heerema; E L Korn; M Link; S Murphy; C H Pui; J Pullen; G Reamon; S E Sallan; H Sather; J Shuster; R Simon; M Trigg; D Tubergen; F Uckun; R Ungerleider Journal: J Clin Oncol Date: 1996-01 Impact factor: 44.544
Authors: S A Shurtleff; A Buijs; F G Behm; J E Rubnitz; S C Raimondi; M L Hancock; G C Chan; C H Pui; G Grosveld; J R Downing Journal: Leukemia Date: 1995-12 Impact factor: 11.528
Authors: Allen R Chauvenet; Paul L Martin; Meenakshi Devidas; Stephen B Linda; Beverly A Bell; Joanne Kurtzberg; Jeanette Pullen; Mark J Pettenati; Andrew J Carroll; Jonathan J Shuster; Bruce Camitta Journal: Blood Date: 2007-04-18 Impact factor: 22.113
Authors: R Peto; M C Pike; P Armitage; N E Breslow; D R Cox; S V Howard; N Mantel; K McPherson; J Peto; P G Smith Journal: Br J Cancer Date: 1977-01 Impact factor: 7.640
Authors: Tatyana V Nasedkina; Natalia A Guseva; Olga A Gra; Olga N Mityaeva; Alexander V Chudinov; Alexander S Zasedatelev Journal: Mol Diagn Ther Date: 2009 Impact factor: 4.074
Authors: Torben S Mikkelsen; Alex Sparreboom; Cheng Cheng; Yinmei Zhou; James M Boyett; Susana C Raimondi; John C Panetta; W Paul Bowman; John T Sandlund; Ching-Hon Pui; Mary V Relling; William E Evans Journal: J Clin Oncol Date: 2011-03-28 Impact factor: 44.544
Authors: C Piette; S Suciu; E Clappier; Y Bertrand; S Drunat; S Girard; K Yakouben; G Plat; N Dastugue; F Mazingue; N Grardel; N van Roy; A Uyttebroeck; V Costa; O Minckes; N Sirvent; P Simon; P Lutz; A Ferster; C Pluchart; M Poirée; C Freycon; M-F Dresse; F Millot; C Chantrain; J van der Werff Ten Bosch; K Norga; C Gilotay; P-S Rohrlich; Y Benoit; H Cavé Journal: Leukemia Date: 2017-09-19 Impact factor: 11.528
Authors: D Bhojwani; D Pei; J T Sandlund; S Jeha; R C Ribeiro; J E Rubnitz; S C Raimondi; S Shurtleff; M Onciu; C Cheng; E Coustan-Smith; W P Bowman; S C Howard; M L Metzger; H Inaba; W Leung; W E Evans; D Campana; M V Relling; C-H Pui Journal: Leukemia Date: 2011-08-26 Impact factor: 11.528